Neurogene Inc. (NASDAQ:NGNE - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Neurogene in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.85) for the quarter. HC Wainwright currently has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene's Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.98) EPS and FY2025 earnings at ($3.68) EPS.
Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter.
Separately, William Blair reaffirmed an "outperform" rating on shares of Neurogene in a research report on Tuesday, March 25th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Neurogene currently has a consensus rating of "Buy" and an average price target of $59.80.
View Our Latest Stock Report on NGNE
Neurogene Stock Performance
Shares of NASDAQ:NGNE traded down $0.81 during mid-day trading on Thursday, reaching $14.52. 98,611 shares of the company's stock were exchanged, compared to its average volume of 210,041. Neurogene has a twelve month low of $13.47 and a twelve month high of $74.49. The firm has a market capitalization of $215.69 million, a price-to-earnings ratio of -3.40 and a beta of 1.01. The business's fifty day moving average price is $16.88 and its 200-day moving average price is $28.76.
Insider Transactions at Neurogene
In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the transaction, the chief financial officer now directly owns 72,343 shares of the company's stock, valued at $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 9.92% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Neurogene
A number of hedge funds have recently added to or reduced their stakes in NGNE. Charles Schwab Investment Management Inc. boosted its holdings in shares of Neurogene by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company's stock worth $1,272,000 after buying an additional 741 shares in the last quarter. FMR LLC boosted its stake in Neurogene by 912.4% during the third quarter. FMR LLC now owns 731,801 shares of the company's stock worth $30,706,000 after acquiring an additional 659,515 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock worth $91,000 after purchasing an additional 1,429 shares during the period. MetLife Investment Management LLC bought a new stake in Neurogene in the third quarter valued at $254,000. Finally, RTW Investments LP increased its stake in Neurogene by 6.0% in the third quarter. RTW Investments LP now owns 1,135,256 shares of the company's stock valued at $47,635,000 after purchasing an additional 64,691 shares in the last quarter. 52.37% of the stock is currently owned by institutional investors.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
See Also
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
